Table of Contents Author Guidelines Submit a Manuscript
Biochemistry Research International
Volume 2015 (2015), Article ID 279356, 9 pages
http://dx.doi.org/10.1155/2015/279356
Review Article

Mechanistic Perspectives of Maslinic Acid in Targeting Inflammation

1School of Biosciences, Taylor’s University, No. 1, Jalan Taylor’s, 47500 Subang Jaya, Selangor, Malaysia
2Department of Preclinical Sciences, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Lot PT 21744, Jalan Sungai Long, Bandar Sungai Long, 43000 Kajang, Selangor, Malaysia

Received 25 July 2015; Accepted 8 September 2015

Academic Editor: Andrei Surguchov

Copyright © 2015 Wei Hsum Yap and Yang Mooi Lim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H.-X. Xu, F.-Q. Zeng, M. Wan, and K.-Y. Sim, “Anti-HIV triterpene acids from Geum japonicum,” Journal of Natural Products, vol. 59, no. 7, pp. 643–645, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. D.-H. Kim, K.-M. Han, I.-S. Chung et al., “Triterpenoids from the flower of Campsis grandiflora K. Schum. as human acyl-CoA: cholesterol acyltransferase inhibitors,” Archives of Pharmacal Research, vol. 28, no. 5, pp. 550–556, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Kalogeropoulos, A. Chiou, M. Ioannou, V. T. Karathanos, M. Hassapidou, and N. K. Andrikopoulos, “Nutritional evaluation and bioactive microconstituents (phytosterols, tocopherols, polyphenols, triterpenic acids) in cooked dry legumes usually consumed in the Mediterranean countries,” Food Chemistry, vol. 121, no. 3, pp. 682–690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M.-C. Yin, M.-C. Lin, M.-C. Mong, and C.-Y. Lin, “Bioavailability, distribution, and antioxidative effects of selected triterpenes in mice,” Journal of Agricultural and Food Chemistry, vol. 60, no. 31, pp. 7697–7701, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Romero, A. García, E. Medina, M. V. Ruíz-Méndez, A. D. Castro, and M. Brenes, “Triterpenic acids in table olives,” Food Chemistry, vol. 118, no. 3, pp. 670–674, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. C. Pérez-Camino and A. Cert, “Quantitative determination of hydroxy pentacyclic triterpene acids in vegetable oils,” Journal of Agricultural and Food Chemistry, vol. 47, no. 4, pp. 1558–1562, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Bianchi, N. Pozzi, and G. Vlahov, “Pentacyclic triterpene acids in olives,” Phytochemistry, vol. 37, no. 1, pp. 205–207, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Yang, J. W. Guang, J. W. Su et al., “Quantitative analysis of 23-hydroxybetulinic acid in mouse plasma using electrospray liquid chromatography/mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 19, no. 12, pp. 1619–1623, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. E. Juan, U. Wenzel, V. Ruiz-Gutierrez, H. Daniel, and J. M. Planas, “Olive fruit extracts inhibit proliferation and induce apoptosis in HT-29 human colon cancer cells,” The Journal of Nutrition, vol. 136, no. 10, pp. 2553–2557, 2006. View at Google Scholar · View at Scopus
  10. H. Lu, C. Xi, J. Chen, and W. Li, “Determination of triterpenoid acids in leaves of Eriobotrya japonica collected at in different seasons,” Zhongguo Zhong Yao Za Zhi, vol. 34, no. 18, pp. 2353–2355, 2009. View at Google Scholar · View at Scopus
  11. N. Banno, T. Akihisa, H. Tokuda et al., “Anti-inflammatory and antitumor-promoting effects of the triterpene acids from the leaves of Eriobotrya japonica,” Biological and Pharmaceutical Bulletin, vol. 28, no. 10, pp. 1995–1999, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D.-H. Kim, K.-M. Han, I.-S. Chung et al., “Triterpenoids from the flower of Campsis grandiflora K. Schum. as human Acyl-CoA: cholesterol acyltransferase inhibitors,” Archives of Pharmacal Research, vol. 28, no. 5, pp. 550–556, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. M. Zou and P. Z. Cong, “Studies on the chemical constituents from roots of Agastache rugosa,” Yao Xue Xue Bao, vol. 26, pp. 906–910, 1991. View at Google Scholar
  14. C. Li, Z. Yang, C. Zhai et al., “Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor α by inhibiting NF-κB signaling pathway,” Molecular Cancer, vol. 9, article 73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Sánchez-Tena, F. J. Reyes-Zurita, S. Díaz-Moralli et al., “Maslinic acid-enriched diet decreases intestinal tumorigenesis in ApcMin/+ mice through transcriptomic and metabolomic reprogramming,” PLoS ONE, vol. 8, no. 3, Article ID e59392, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Márquez Martín, R. de la Puerta Vázquez, A. Fernández-Arche, and V. Ruiz-Gutiérrez, “Supressive effect of maslinic acid from pomace olive oil on oxidative stress and cytokine production in stimulated murine macrophages,” Free Radical Research, vol. 40, no. 3, pp. 295–302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Huang, T. Guan, Y. Qian et al., “Anti-inflammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factor-kappa B,” European Journal of Pharmacology, vol. 672, no. 1–3, pp. 169–174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Hussain Shaik, S. N. Rasool, M. A. Kareem, G. S. Krushna, P. M. Akhtar, and K. L. Devi, “Maslinic acid protects against isoproterenol-induced cardiotoxicity in albino Wistar rats,” Journal of Medicinal Food, vol. 15, no. 8, pp. 741–746, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Parra, F. Rivas, P. E. Lopez et al., “Solution- and solid-phase synthesis and anti-HIV activity of maslinic acid derivatives containing amino acids and peptides,” Bioorganic & Medicinal Chemistry, vol. 17, no. 3, pp. 1139–1145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Moneriz, J. Mestres, J. M. Bautista, A. Diez, and A. Puyet, “Multi-targeted activity of maslinic acid as an antimalarial natural compound,” FEBS Journal, vol. 278, no. 16, pp. 2951–2961, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Qian, T. Guan, X. Tang et al., “Maslinic acid, a natural triterpenoid compound from Olea europaea, protects cortical neurons against oxygen-glucose deprivation-induced injury,” European Journal of Pharmacology, vol. 670, no. 1, pp. 148–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. P. Montilla, A. Agil, M. C. Navarro et al., “Antioxidant activity of maslinic acid, a triterpene derivative obtained from Olea europaea,” Planta Medica, vol. 69, no. 5, pp. 472–474, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Sánchez-González, G. Lozano-Mena, M. E. Juan, A. García-Granados, and J. M. Planas, “Assessment of the safety of maslinic acid, a bioactive compound from Olea europaea L.,” Molecular Nutrition and Food Research, vol. 57, no. 2, pp. 339–346, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Sun, Y. Tang, T. Ding, M. Liu, and X. Wang, “Investigation of cytochrome P450 inhibitory properties of maslinic acid, a bioactive compound from Olea europaea L., and its structure-activity relationship,” Phytomedicine, vol. 22, no. 1, pp. 56–65, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. J. D. Connolly and R. A. Hill, “Triterpenoids,” Natural Product Reports, vol. 19, no. 4, pp. 494–513, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Xu, G. C. Fazio, and S. P. T. Matsuda, “On the origins of triterpenoid skeletal diversity,” Phytochemistry, vol. 65, no. 3, pp. 261–291, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Glinski and K. L. Branly, “Pentacyclic triterpenes,” US Patent 6303589, 2002.
  28. M. B. Sporn, K. T. Liby, M. M. Yore, L. Fu, J. M. Lopchuk, and G. W. Gribble, “New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress,” Journal of Natural Products, vol. 74, no. 3, pp. 537–545, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Del Carmen Recio, R. M. Giner, S. Máñez, and J. L. Ríos, “Structural requirements for the anti-inflammatory activity of natural triterpenoids,” Planta Medica, vol. 61, no. 2, pp. 182–185, 1995. View at Publisher · View at Google Scholar · View at Scopus
  30. H. L. Ziegler, H. Franzyk, M. Sairafianpour et al., “Erythrocyte membrane modifying agents and the inhibition of Plasmodium falciparum growth: structure-activity relationships for betulinic acid analogues,” Bioorganic and Medicinal Chemistry, vol. 12, no. 1, pp. 119–127, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Prades, O. Vögler, R. Alemany et al., “Plant pentacyclic triterpenic acids as modulators of lipid membrane physical properties,” Biochimica et Biophysica Acta—Biomembranes, vol. 1808, no. 3, pp. 752–760, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Syrovets, B. Büchele, E. Gedig, J. R. Slupsky, and T. Simmet, “Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIα,” Molecular Pharmacology, vol. 58, no. 1, pp. 71–81, 2000. View at Google Scholar · View at Scopus
  33. A. Marquez-Martin, R. De La Puerta, A. Fernandez-Arche, V. Ruiz-Gutierrez, and P. Yaqoob, “Modulation of cytokine secretion by pentacyclic triterpenes from olive pomace oil in human mononuclear cells,” Cytokine, vol. 36, no. 5-6, pp. 211–217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Ricciotti and G. A. Fitzgerald, “Prostaglandins and inflammation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 5, pp. 986–1000, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Stables and D. W. Gilroy, “Old and new generation lipid mediators in acute inflammation and resolution,” Progress in Lipid Research, vol. 50, no. 1, pp. 35–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Piper and J. Vane, “The release of prostaglandins from lung and other tissues,” Annals of the New York Academy of Sciences, vol. 180, pp. 363–385, 1971. View at Publisher · View at Google Scholar · View at Scopus
  37. C. N. Serhan, M. Hamberg, and B. Samuelsson, “Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes,” Biochemical and Biophysical Research Communications, vol. 118, no. 3, pp. 943–949, 1984. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Samuelsson, S.-E. Dahlen, J. A. Lindgren, C. A. Rouzer, and C. N. Serhan, “Leukotrienes and lipoxins: structures, biosynthesis, and biological effects,” Science, vol. 237, no. 4819, pp. 1171–1176, 1987. View at Publisher · View at Google Scholar · View at Scopus
  39. J. H. Capdevilla, J. R. Falck, E. Dishman, and A. Karara, “Cytochrome P-450 arachidonate oxygenase,” Methods in Enzymology, vol. 187, pp. 385–394, 1990. View at Publisher · View at Google Scholar · View at Scopus
  40. E. M. Smyth, T. Grosser, M. Wang, Y. Yu, and G. A. FitzGerald, “Prostanoids in health and disease,” Journal of Lipid Research, vol. 50, pp. S423–S428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Hamberg and B. Samuelsson, “Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 70, no. 3, pp. 899–903, 1973. View at Publisher · View at Google Scholar · View at Scopus
  42. D. H. Nugteren and E. Hazelhof, “Isolation and properties of intermediates in prostaglandin biosynthesis,” Biochimica et Biophysica Acta, vol. 326, no. 3, pp. 448–461, 1973. View at Publisher · View at Google Scholar · View at Scopus
  43. R. N. Dubois, S. B. Abramson, L. Crofford et al., “Cyclooxygenase in biology and disease,” The FASEB Journal, vol. 12, no. 12, pp. 1063–1073, 1998. View at Google Scholar · View at Scopus
  44. J. D. Morrow, W. G. Parsons III, and L. J. Roberts II, “Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid,” Prostaglandins, vol. 38, no. 2, pp. 263–274, 1989. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Tanaka, S. L. Ward, and W. L. Smith, “Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes,” Journal of Biological Chemistry, vol. 262, no. 3, pp. 1374–1381, 1987. View at Google Scholar · View at Scopus
  46. H. Hayashi, Y. Fujii, K. Watanabe, Y. Urade, and O. Hayaishi, “Enzymatic conversion of prostaglandin H2 to prostaglandin F(2α) by aldehyde reductase from human liver: comparison to the prostaglandin F synthetase from bovine lung,” Journal of Biological Chemistry, vol. 264, no. 2, pp. 1036–1040, 1989. View at Google Scholar · View at Scopus
  47. S. Moncada, R. Gryglewski, S. Bunting, and J. R. Vane, “An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation,” Nature, vol. 263, no. 5579, pp. 663–665, 1976. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Ullrich and M. Haurand, “Thromboxane synthase as a cytochrome P450 enzyme,” Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 11, pp. 105–110, 1983. View at Publisher · View at Google Scholar · View at Scopus
  49. C. E. Trebino, J. L. Stock, C. P. Gibbons et al., “Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 9044–9049, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. D. F. Legler, M. Bruckner, E. Uetz-von Allmen, and P. Krause, “Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances,” International Journal of Biochemistry & Cell Biology, vol. 42, no. 2, pp. 198–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. J. Lewis, D. J. Nelson, and M. F. Sugrue, “On the ability of prostaglandin E1 and arachidonic acid to modulate experimentally induced oedema in the rat paw,” British Journal of Pharmacology, vol. 55, no. 1, pp. 51–56, 1975. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Kaley, T. H. Hintze, M. Panzenbeck, and E. J. Messina, “Role of prostaglandins in microcirculatory function,” Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 13, pp. 27–35, 1985. View at Google Scholar · View at Scopus
  53. A. N. Hata and R. M. Breyer, “Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation,” Pharmacology & Therapeutics, vol. 103, no. 2, pp. 147–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Moriyama, T. Higashi, K. Togashi et al., “Sensitization of TRPVI by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins,” Molecular Pain, vol. 1, article 3, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Minami, H. Nakano, T. Kobayashi et al., “Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice,” British Journal of Pharmacology, vol. 133, no. 3, pp. 438–444, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. M. C. Catley, J. E. Chivers, L. M. Cambridge et al., “IL-1 beta-dependent activation of NF-kappa B mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase,” FEBS Letters, vol. 547, no. 1–3, pp. 75–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Yamamoto, T. Arakawa, N. Ueda, and S. Yamamoto, “Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells,” Journal of Biological Chemistry, vol. 270, no. 52, pp. 31315–31320, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. F. D'Acquisto, T. Iuvone, L. Rombolà, L. Sautebin, M. Di Rosa, and R. Carnuccio, “Involvement of NF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages,” FEBS Letters, vol. 418, no. 1-2, pp. 175–178, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Ochi, Y. Ohkubo, and S. Mutoh, “Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice,” Biochemical Pharmacology, vol. 66, no. 6, pp. 1055–1060, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. L. K. Myers, A. H. Kang, A. E. Postlethwaite et al., “The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis,” Arthritis & Rheumatism, vol. 43, no. 12, pp. 2687–2693, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Chen, E. Boilard, P. A. Nigrovic et al., “Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis,” Arthritis & Rheumatism, vol. 58, no. 5, pp. 1354–1365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. I. A. Mardini and G. A. FitzGerald, “Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs,” Molecular Interventions, vol. 1, no. 1, pp. 30–38, 2001. View at Google Scholar · View at Scopus
  63. C. D. Funk and G. A. FitzGerald, “COX-2 inhibitors and cardiovascular risk,” Journal of Cardiovascular Pharmacology, vol. 50, no. 5, pp. 470–479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Zamora, Y. Vodovotz, and T. R. Billiar, “Inducible nitric oxide synthase and inflammatory diseases,” Molecular Medicine, vol. 6, no. 5, pp. 347–373, 2000. View at Google Scholar · View at Scopus
  65. P. Osuna, “Use of maslinic acid for the treatment of diseases and the symptoms thereof by means of cox-2 inhibition,” US Patent US 20110105611A1, 2011.
  66. E. Fosslien, “Molecular pathology of cyclooxygenase-2 in neoplasia,” Annals of Clinical and Laboratory Science, vol. 30, no. 1, pp. 3–21, 2000. View at Google Scholar · View at Scopus
  67. S. Y. Park, C. W. Nho, D. Y. Kwon, Y.-H. Kang, K. W. Lee, and J. H. Y. Park, “Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor-1α signalling,” British Journal of Nutrition, vol. 109, no. 2, pp. 210–222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. T. D. Gilmore, “Introduction to NF-kappaB: players, pathways, perspectives,” Oncogene, vol. 25, no. 51, pp. 6680–6684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. F. E. Chen and G. Ghosh, “Regulation of DNA binding by Rel/NF-κB transcription factors: structural views,” Oncogene, vol. 18, no. 49, pp. 6845–6852, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Yamamoto and R. B. Gaynor, “Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer,” The Journal of Clinical Investigation, vol. 107, no. 2, pp. 135–142, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. W. Hsum, W. T. Yew, P. L. V. Hong et al., “Cancer chemopreventive activity of maslinic acid: suppression of COX-2 expression and inhibition of NF-κB and AP-1 activation in raji cells,” Planta Medica, vol. 77, no. 2, pp. 152–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. F. J. Reyes-Zurita, G. Pachón-Peña, D. Lizárraga, E. E. Rufino-Palomares, M. Cascante, and J. A. Lupiáñez, “The natural triterpene maslinic acid induces apoptosis in HT29 colon cancer cells by a JNK-p53-dependent mechanism,” BMC Cancer, vol. 11, article 154, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. D.-M. Wu, D. Zhao, D.-Z. Li, D.-Y. Xu, W.-F. Chu, and X.-F. Wang, “Maslinic acid induces apoptosis in salivary gland adenoid cystic carcinoma cells by Ca2+-evoked p38 signaling pathway,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 383, no. 3, pp. 321–330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Li, Z. Yang, Z. Li et al., “Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways,” Journal of Bone and Mineral Research, vol. 26, no. 3, pp. 644–656, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Y. Mooi, W. T. Yew, Y. W. Hsum, K. K. Soo, L. S. Hoon, and Y. C. Chieng, “Suppressive effect of maslinic acid on PMA-induced protein kinase C in human B-lymphoblastoid cells,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1177–1182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Medeiros, M. F. Otuki, M. C. W. Avellar, and J. B. Calixto, “Mechanisms underlying the inhibitory actions of the pentacyclic triterpene α-amyrin in the mouse skin inflammation induced by phorbol ester 12-O-tetradecanoylphorbol-13-acetate,” European Journal of Pharmacology, vol. 559, no. 2-3, pp. 227–235, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Murakami, Y. Nakatani, G.-I. Atsumi, K. Inoue, and I. Kudo, “Regulatory functions of phospholipase A2,” Critical Reviews in Immunology, vol. 17, no. 3-4, pp. 225–283, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Xu, Y.-I. Weng, A. Simoni et al., “Role of PKC and MAPK in cytosolic PLA2 phosphorylation and arachadonic acid release in primary murine astrocytes,” Journal of Neurochemistry, vol. 83, no. 2, pp. 259–270, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. R. H. Schaloske and E. A. Dennis, “The phospholipase A2 superfamily and its group numbering system,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1761, no. 11, pp. 1246–1259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. S.-K. Han, E. T. Yoon, and W. Cho, “Bacterial expression and characterization of human secretory class V phospholipase A2,” Biochemical Journal, vol. 331, no. 2, pp. 353–357, 1998. View at Publisher · View at Google Scholar · View at Scopus
  81. S. T. Reddy, M. V. Winstead, J. A. Tischfield, and H. R. Herschman, “Analysis of the secretory phospholipase A2 that mediates prostaglandin production in mast cells,” The Journal of Biological Chemistry, vol. 272, no. 21, pp. 13591–13596, 1997. View at Publisher · View at Google Scholar · View at Scopus
  82. W. H. Yap, B. I. Laweeza Meetoo, and N. Ahemad, “Elucidating the molecular mechanisms of interaction between maslinic acid and human group V-secreted phospholipase A2 (hGV-sPLA2),” in Proceedings of the Joint Malaysia-UK Symposium on Natural Product Chemistry and Drug Discovery, International Medical University, Kuala Lumpur, Malaysia, 2014.